Fentanyl Sublingual Spray (FSS)

DRUG3 trials

Sponsors

INSYS Therapeutics Inc, M.D. Anderson Cancer Center

Conditions

Advanced CancersBioavailabilityChronic Pain

Phase 2

Sublingual Fentanyl for the Management of Breakthrough Pain

TerminatedNCT02514252

M.D. Anderson Cancer CenterAdvanced Cancers

Start: 2016-02-02End: 2019-11-04Updated: 2021-05-18

Phase 3

Fentanyl Sublingual Spray for the Treatment of Acute Procedure-related Pain in a Monitored Setting

WithdrawnNCT02138409

INSYS Therapeutics IncChronic Pain

Start: 2017-12-30End: 2018-01-31Updated: 2018-01-04

Unknown Phase

Exploratory Bioavailability of Fentanyl Sublingual Spray Under Fasting Conditions

CompletedNCT02138396

INSYS Therapeutics IncBioavailability

Start: 2014-01-31End: 2014-01-31Updated: 2014-12-12